Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Table 1
Clinical and biochemical characteristics of patients with serological diagnosis of COVID-19 and Hypertensive Pregnancy Disorders. Source: Data obtained from the Obstetrics inpatient Department. Hospital Nacional Edgardo Rebagliati Martins. March-August 2020. AST: Aspartate aminotransferase. * Patients with lymphopenia (lymphocytes <1000 cells/mm³).

| Case | Age | Gestational Age | Parity | Symptoms | White blood cell x 10^9 L^-1 | AST (U/L) | Delivery | Hypertensive Pregnancy Disorder |
|------|-----|-----------------|--------|----------|-----------------------------|----------|----------|---------------------------------|
| 1    | 39  | 39              | Multiparity | Asymptomatic | 7.5 (16.7) | 64         | Caesarean Section | Severe Preeclampsia |
| 2    | 33  | 34              | Multiparity | Asymptomatic | 9.1 (31.9) | 53         | Caesarean Section | Severe Preeclampsia |
| 3    | 43  | 40              | Multiparity | Asymptomatic | 12.3 (28.4) | 36         | Caesarean Section | Severe Preeclampsia |
| 4    | 21  | 36              | Nulliparity | Asymptomatic | 7.4 (25.6) | 42         | Caesarean Section | Mild Preeclampsia |
| 5    | 31  | 33              | Nulliparity | Asymptomatic | 9.3 (27)  | 53         | Caesarean Section | Severe Preeclampsia |
| 6    | 33  | 38              | Multiparity | Asymptomatic | 7.7 (22.2) | 14         | Caesarean Section | Gestational Hypertension |
| 7    | 45  | 38              | Multiparity | Asymptomatic | 14.5 (32.8) | 25         | Caesarean Section | Severe Preeclampsia |
| 8    | 42  | 40              | Multiparity | Headache    | 8.8 (19.2) | 51         | Vaginal Delivery   | Gestational Hypertension |
| 9    | 32  | 40              | Multiparity | Asymptomatic | 19.2 (4.73) | 39         | Vaginal Delivery   | Mild Preeclampsia |
| 10   | 37  | 40              | Multiparity | Asymptomatic | 8.4 (35.3) | 16         | Caesarean Section | Severe Preeclampsia |
| 11   | 45  | 34              | Nulliparity | Asymptomatic | 6.0 (15.8) | 27         | Caesarean Section | Severe Preeclampsia and Eclampsia |
| 12   | 33  | 39              | Multiparity | Asymptomatic | 10.2 (33.9) | 27         | Caesarean Section | Gestational Hypertension |
| 13   | 29  | 34              | Multiparity | Asymptomatic | 18 (3.7) | 904        | Caesarean Section | Severe Preeclampsia and Eclampsia |
| 14   | 39  | 39              | Multiparity | Asymptomatic | 11 (27) | 64         | Cesarean Hysterectomy | HeliP Syndrome |
| 15   | 29  | 36              | Nulliparity | Asymptomatic | 6.8 (21.6) | 449        | Caesarean Section | HeliP Syndrome |
| 16   | 32  | 37              | Multiparity | Asymptomatic | 10.1 (27.5) | 16         | Caesarean Section | Mild Preeclampsia |
| 17   | 22  | 33              | Nulliparity | Cough       | 7.8 (17.8) | 59         | Caesarean Section | HeliP Syndrome* |
| 18   | 27  | 23              | Nulliparity | Cough       | 7.8 (17.8) | 54         | Caesarean Section | HeliP Syndrome |
| 19   | 24  | 39              | Nulliparity | Asymptomatic | 12.7 (22.9) | 33         | Caesarean Section | Severe Preeclampsia |
| 20   | 31  | 33              | Multiparity | Fever       | 9.3 (29.5) | 288        | Vaginal Delivery   | HeliP Syndrome* |

Declaration of Competing Interest
The authors report no declarations of interest.

References
[1] Todros T, Mastrozzo B, De Francis S. COVID-19 infection: ACE2, pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol 2020. doi:http://dx.doi.org/10.1016/ejogr.2020.08.007.
[2] Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, Serrano B, et al. Preeclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG An Int J Obstet Gynaecol 2020. doi:http://dx.doi.org/10.1111/1471-0528.16339 1471-0528.16339.
[3] Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (80-) 2020;367:1444–5. doi: http://dx.doi.org/10.1126/science.abb2762.
[4] Ahmed I, Eltaweel N, Antoun L, Rehal A. Severe pre-eclampsia complicated by acute fatty liver disease of pregnancy, HELLP syndrome and acute kidney injury following SARS-CoV-2 infection. BMJ Case Rep 2020;13:e237521. doi:http://dx.doi.org/10.1136/bcr-2020-237521.
[5] Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental pathology in COVID-19: Am J Clin Pathol 2020;154:23–32. doi:http://dx.doi.org/10.1093/ajcp/aqaa089.
[6] Huerta Saenz IH, Elias Estrada JC, Campos Del Castillo K, Muñoz Taya R, Coronado JC. Características maternoperinatales de gestantes COVID-19 en un hospital nacional de Lima, Perú. Rev Peru Ginecol Obstet. 2020;66(2). doi:http://dx.doi.org/10.31403/rpgo.v66i2245.

Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India

Dear Editor,

Asymptomatic women with coronavirus disease 2019 (COVID-19) are at risk of infecting their newborns and also pose a risk to healthcare providers and other patients [1,2,3]. Considering this, Indian Council of Medical Research (ICMR) recommended universal testing for SARS-CoV-2 in pregnant women [4]. Maharashtra is the worst-hit state in India and universal screening strategy for pregnant women was implemented in several public hospitals during this time. Herein, we report the outcome of implementation of this strategy.

Women presenting in labour or likely to deliver in next 5 days were screened for SARS-CoV-2 as per ICMR guidelines [4]. Data from 25th April to 20th May, 2020 was collected from 15 participating hospitals of PregCovid registry network (https://pregcovid.com/). In all, 141/1140 pregnant women were tested positive for SARS-CoV-2 resulting in a prevalence of 12.3% (Mean 9.4, 95% CI 6.6 – 12.1) in Maharashtra, India [Fig. 1A]. The prevalence of SARS-CoV-2 infection in women varied (0-40%) across the different hospitals in the state. For estimation of numbers of symptomatic and asymptomatic SARS-CoV-2 positive
pregnant women, the data of 141 women was pooled with data from Topiwala National Medical College (TNMC) & BYL Nair Hospital TNMC Mumbai (n = 180) which exclusively caters COVID-19 patients (n = 180). Of the 321 SARS-CoV-2 positive women only 37 (range 0-17%) women were symptomatic (Fig. 1B). The prevalence of symptomatic pregnant women is 11.5% (Mean 6.8, 95% CI 2.4-11.2) while that of asymptomatic pregnant women is 88.5% (Mean 79.8, 95% CI 75.7-83.9) [Fig. 1B]. The proportion of symptomatic to asymptomatic individuals varied greatly across the different cities (not shown). Our results estimate presence of one symptomatic to every nine asymptomatic pregnant women. This is in concordance to the number proposed based on mathematical calculations and some observational data [5].

This data on undocumented or “steady state” infections in pregnant women is useful for ensuring safe obstetric and neonatal services and assessing the burden of COVID-19 in the region to plan strategies on strengthening or relaxing mass social distancing measures. We strongly recommend that the strategy of universal testing of pregnant women admitted for delivery is essential and must be implemented rigorously not just to protect the women and their newborns; but also, the healthcare workers and curb spread of the infection in the community.

Declaration of Competing Interest

All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The support of the PregCOVID registry network (Appendix 1) is gratefully acknowledged. PregCovid registry is funded by intramural grant of ICMR-NIRRH (RA/924/06-2020).

Appendix 1

Participants of PregCovid Registry Network as on 18.08.2020

1 Dr Niraj Mahajan, Associate Professor and COVID-19 Maternity Nodal Officer, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai
2 Dr Ramesh Bhosale, Professor and Head, Department of Obstetrics & Gynecology, Byramjee Jeejeebhoy Medical College, Pune
3 Dr Shrinivas Gaddappa, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Aurangabad
4 Dr. Vidya Tirankar, Professor and Head, Department of Obstetrics & Gynecology, Dr Vaishampayan Memorial Government Medical College, Solapur
5 Dr Ashok Anand, Professor and Head, Department of Obstetrics & Gynecology, Grant Medical College and J J Group of Hospitals, Mumbai
6 Dr Tushar Palve, Medical Superintendent, Cama And Albless Hospital, Mumbai
7 Dr M.R. Waikar, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Nagpur
8 Dr. Sarika Wankhede, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Chandrapur
9 Dr Jyoti Rokade, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Miraj
10 Dr. Arun Morey, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Dhule
11 Dr Prashant Uikey, Professor and Head, Department of Obstetrics & Gynecology, Indira Gandhi Medical College, Nagpur
12 Dr. S.R. Wakode, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Nanded
13 Dr. Mangal Shinde, Professor and Head, Department of Obstetrics & Gynecology, Vilsrao Deshmukh Government Institute of Medical Sciences, Latur
14 Dr. Jitendra Deshmukh, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Gondia
15 Dr. Shrirish Shanbhag, Professor and Head, Department of Obstetrics & Gynecology, Rajarshi Chhatrapati Shahu Maharaj Government Medical College, Kolhapur
16 Dr. Rohidas Chavan, Professor and Head, Department of Obstetrics & Gynecology Vasanthrao Naik Government Medical College, Yavatmal
17 Dr Shyamkumar Sirsam, Professor and Head, Department of Obstetrics & Gynecology Government Medical College, Akola
18 Dr. Sanjay Bansode, Professor and Head, Department of Obstetrics & Gynecology Government Medical College, Jalgaon
19 Dr. Swati Kagne, Associate Professor, Department of Obstetrics & Gynecology Government Medical College, Ambejogai
20 Dr Uma Wankhede, Professor and Head, Department of Obstetrics & Gynecology, Government Medical College, Baranati
Perinatal mortality and morbidity of SARS-COV-2 infection during pregnancy in European countries: Findings from an international study

Keywords:
COVID-19
SARS-COV-2
Pregnancy

Dear Editor,

After being epidemic in China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) infection has rapidly spread in many countries as a global pandemic, with the number of affected cases dramatically increasing worldwide on a daily basis. Although the median age of hospitalized patients with confirmed infection is usually more advanced [1], with older age reported to be associated to higher mortality rate [2], physiological adaptations occurring during pregnancy have been claimed to be potentially responsible for a more severe respiratory disease, thus leading to higher rates of maternal and fetal complications [3,4].

Evidence has been accumulating rapidly in the last months to provide early information to help with counseling and care of pregnant women with SARS-CoV-2 infection, and despite the relatively short time from the pandemic outbreak, a multitude of systematic reviews have been published on the topic of SARS-COV-2 infection and COVID-19 disease during pregnancy. However, these studies often share important limitations that might affect the robustness of the results [1,3–6].

Since Europe is currently handling the real possibility of a “second wave”, with a new, daily, progressive increase in the number of infected patients after governments’ mitigation policies to minimize the virus transmission, there are still several outstanding issues that should be settled soon to guide the antenatal counselling and management of women with COVID-19 during pregnancy.

Here we present a secondary analysis on perinatal mortality and morbidity in European compared with non-European pregnant women involved in one of the largest retrospective cohort studies on COVID-19 during pregnancy [7,8]. This was a multinational, retrospective cohort study that included all pregnant women with a laboratory-confirmed SARS-CoV-2 infection, diagnosed between February 1, 2020 and April 30, 2020, in 72 centers from 22 different countries in Europe, Asia, North and South America and Australia (Argentina, Australia, Belgium, Brazil, Colombia, Czech Republic, Finland, Germany, Greece, Israel, Italy, North Macedonia, Peru, Portugal, Republic of Kosovo, Romania, Russia, Serbia, Slovenia, Spain, Turkey, and United States) [7]. All infected women were diagnosed antepartum during pregnancy, on the basis of The World Health Organization (WHO) interim guidance [9] (a confirmed case of SARS-CoV-2 was defined as a positive result on real-time reverse-transcriptase-polymerase-chain-reaction assay of nasal and pharyngeal swab specimens) [10,11]. Neonates from mother positive to SARS-COV-2 were usually tested within 24 h after delivery with RT-PCR assay of nasal and pharyngeal swab (Table 1).

The findings from this secondary analysis focused on regional differences shows that in European countries the rate of stillbirth was significantly lower, compared with non-European countries (1.0 % vs 7.4 %, OR: 0.12, p = 0.02), while the rate of neonatal death was similar when evaluating only pregnancies with live-born. In these subset of pregnancies, the rate of admission in neonatal intensive care unit (NICU) was significantly lower in European compared with non-European countries (23.9 % vs 42.0 %, OR: 0.43, p = 0.01). Finally, there was no difference between European and non-European countries in terms of intrauterine growth restriction, preterm birth before 37 weeks of gestation, possible vertical transmission and low birth weight (Table 2).

Thus, pregnant women infected with SARS-COV-2 had better perinatal outcomes in European compared with non-European countries, despite being significantly older and having a significantly higher rate of pre-existing chronic diseases. However, gestational age at infection was significantly higher in European women. In this scenario, the lack of data in literature on SARS-COV-2 infection during the first and early second trimester does not allow to ascertain whether a seroconversion occurring early in pregnancy may increase the risk of adverse perinatal outcomes.

References
[1] Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med 2020; 382:2163–4. doi:http://dx.doi.org/10.1056/NEJMoa2009316.
[2] Gagliardi L, Danieli R, Suriano G, Vaccaro A, Tripodi G, Rusconi F, et al. Universal SARS-CoV-2 testing of pregnant women admitted for delivery in two Italian regions. American Journal of Obstetrics & Gynecology 2020;232, doi:http://dx.doi.org/10.1016/j.ajo.2020.03.017.
[3] Shende P, Gaikwad P, Chandhwar M, Ukey P, Bhide A, Patel V, et al. Persistence of SARS-CoV-2 in the first trimester placenta leading to vertical transmission and fetal demise from an asymptomatic mother. MedRxiv 2020. doi:http://dx.doi.org/10.1101/2020.08.18.20177121 2020.08.18.20177121.
[4] INDIAN COUNCIL OF MEDICAL RESEARCH, DEPARTMENT OF HEALTH RESEARCH. Strategy for COVID-19 testing for pregnant women in India (Version 1, dated 20/04/2020), 2020.
[5] Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368:489–93. doi:http://dx.doi.org/10.1126/science.abb3221–234 https://doi.org/10.1057/AOOG.0000000000003983.

Rakesh Waghmarea,b,1,2
Rahul Gajbhiye1
Niraj N. Mahajan MDd
Deepak Modi1
Sanjay Mukherjeee,∗
Smita D. Mahalec,∗

∗Corresponding authors.
E-mail addresses: psec.mededu@maharashtra.gov.in (S. Mukherjee),
smitahale@hotmail.com,dir@nirrh.res.in (S. Mahale).

Received 18 August 2020

Medical Education and Drugs Department, Government of Mahara-
ashtra, India

Department of Community Medicine, Grant GovernmentMedical
College and Sir J. J.Group of Hospitals, Mumbai, India

ICMR-National Institute for Research in Reproductive Health,
Mumbai, India

Topiwala National Medical College & BYL Nair Charitable Hospital,
Mumbai, India

These authors contributed equally

Dr. Sanjay Mukherjee, MBBS, IAS, Former Secretary, Medical
Education and Drugs Department, Govt. of Maharashtra, Present
affiliation, Vice Chairman and Managing Director, City and Industrial
Development Corporation (CIDCO)